BioForce Nanosciences Reports Q1 2025 Financial Results with Increased Net Loss

BioForce Nanosciences Holdings, Inc. reported its financial results for the first quarter of 2025, revealing a net loss of $934,650, a significant increase from the $130,813 loss recorded in the same period of 2024. The company reported no sales revenue for both the three months ended March 31, 2025, and March 31, 2024, resulting in a gross profit of $0. Operating expenses rose slightly to $133,455, compared to $130,813 in the prior year, primarily due to increased general and administrative costs. The company's accumulated deficit now stands at $162,054,816, reflecting ongoing financial challenges.

In terms of balance sheet performance, BioForce's total assets increased to $13,799 as of March 31, 2025, up from $862 at the end of 2024. However, total liabilities remained unchanged at $275,041, indicating a significant reliance on accrued expenses and related party transactions to sustain operations. The company’s stockholders' deficit improved to $(261,242) from $(2,301,592) at the end of the previous fiscal year, largely due to the issuance of 4,250,000 shares to settle accrued compensation liabilities.

Strategically, BioForce continues to focus on its mission to become a leading provider of nutritional supplements. The company is actively working on expanding its product offerings, particularly the "BioForce Eclipse" nutritional powder, and aims to enhance its marketing efforts through direct marketing and B2B sales campaigns. The company has established a supplier agreement with a manufacturer in Virginia, allowing it to market its products without non-compete agreements, which could facilitate broader distribution.

Operationally, BioForce has not reported any customer orders or product sales during the first quarter of 2025, which raises concerns about market penetration and product adoption rates. The company is targeting various retail channels, including health food stores and online platforms, to increase its market presence. As of the latest report, the company has not disclosed any significant changes in employee headcount or geographic expansion plans.

Looking ahead, BioForce acknowledges the need for additional capital to support its operations and business plan. The management has indicated that without sufficient revenue generation or financing, the company may face challenges in continuing its operations. The outlook remains uncertain, as the company is dependent on its ability to implement its marketing strategies effectively and secure necessary funding to achieve profitability.